Watson Pharmaceuticals, Inc. Eyes $600M Sigma Pharmaceuticals Generics Deal

SYDNEY (Reuters) - Watson Pharmaceuticals Inc (WPI.N) is considering bidding for the generics business of Australia's Sigma Pharmaceuticals (SIP.AX), valued at around A$600 million, The Age newspaper reported on Monday without citing sources.
MORE ON THIS TOPIC